Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Hot Flashes 4Breast Neoplasms 3Prostatic Neoplasms 2Head and Neck Neoplasms 2Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 1Sleep Wake Disorders 1Lymphoma, Follicular 1Depressive Disorder, Major 1Depressive Disorder 1Depression 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Cancer Pain 1Breast Carcinoma In Situ 1Bipolar Disorder 1Adenocarcinoma 1

Interventions

Cisplatin 253Radiotherapy 176Cetuximab 145pembrolizumab 120Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 77Radiotherapy, Intensity-Modulated 69Nivolumab 37Radiation 30Drug Therapy 30Erlotinib Hydrochloride 26Gemcitabine 25Cyclophosphamide 22Gefitinib 21Surveys and Questionnaires 20Standard of Care 20Surgical Procedures, Operative 19Pemetrexed 19durvalumab 18Magnetic Resonance Spectroscopy 17Capecitabine 17Radiosurgery 16Celecoxib 16atezolizumab 15Filgrastim 15Amifostine 15130-nm albumin-bound paclitaxel 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Head and Neck Neoplasms × Venlafaxine Hydrochloride × Clear all
NCT04977271 2025-02-04

Mood Disorders in Head and Neck Cancer Patients

University of Alabama at Birmingham

Phase 4 Withdrawn
Head & Neck

Depressive Disorder, Head and Neck Neoplasms

NCT05724849 2024-01-18

Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer

Vanderbilt University Medical Center

Phase 2 Withdrawn
Head & Neck

Depression, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡